Abstracts Archive - Page 1884 of 2425 - ACR Meeting Abstracts

Abstract Number: 2521 • 2014 ACR/ARHP Annual Meeting
Analysis on Predictors for Long-Term Clinical Efficacies of Golimumab in Patients with Rheumatoid Arthritis
Tsutomu Takeuchi¹, Yutaka Ishii², Kimie Tanaka³, Yoshifumi Ukyo⁴ and Hiroshi Sekine⁵, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Medical Affaires, Janssen Pharmaceutical K.K, Tokyo, Japan, ³Medical Affairs, Janssen Pharmaceutical K.K., Tokyo, Japan, ⁴Biostatistics Devision, Janssen Pharmaceutical K.K., Japan, Tokyo, Japan, ⁵Medical Affaires, Janssen Pharmaceutical K.K., Tokyo, Japan
Background/Purpose The GO-FORTH, phase 2/3 clinical trial was conducted to examine the efficacy and safety of Golimumab (GLM) plus MTX in Japanese patients (pts) with…
Abstract Number: 2520 • 2014 ACR/ARHP Annual Meeting
Patient, Genetic and Disease Factors Influence the Response to the Disease Modifying Anti-Rheumatic Drug Leflunomide
Michael D. Wiese¹, Ashley Hopkins², Llew Spargo³, Leah McWilliams³, Catherine O'Doherty², Leslie G. Cleland³ and Susanna Proudman⁴, ¹Division of Health Sciences, School of Pharmacy, University of South Australia, Adelaide, Australia, ²School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, ³Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁴Department of Rheumatology, Royal Adelaide Hospital, SA, Australia
Background/Purpose . Leflunomide is a disease modifying anti-rheumatic drug that is used in the treatment of rheumatoid arthritis (RA). Leflunomide is converted to teriflunomide by the…
Abstract Number: 2518 • 2014 ACR/ARHP Annual Meeting
What Is the Level of Agreement Between Disease Activity Indices and Response Criteria Among Rheumatoid Arthritis Patients Treated with TNF Inhibitors?
Edward C. Keystone¹, Philip Baer², J. Antonio Avina-Zubieta³, Anna Jaroszynska⁴, Jude Rodrigues⁵, Regan Arendse⁶, Dalton Sholter⁷, Michael Starr⁸, Ariel Masetto⁹, John S. Sampalis¹⁰, Emmanouil Rampakakis¹⁰, Francois Nantel¹¹, May Shawi¹¹, Allen J Lehman¹² and Susan Otawa¹², ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Private Practice, Scarborough, ON, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Private Practice, Burlington, ON, Canada, ⁵Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷University of Alberta, Edmonton, AB, Canada, ⁸Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁹Rheumatology, CHUS, Fleurimont, QC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Several standardized response criteria and disease activity indices are used to assess treatment efficacy in rheumatoid arthritis (RA). These measures comprise different types and…
Abstract Number: 2519 • 2014 ACR/ARHP Annual Meeting
Are Patients with Rheumatoid Arthritis Initiating a TNF Biologic Comparable to Patients Initiating a Non TNF?
Kaleb Michaud^1,2, Kunal Gandhi³, Teresa Simon⁴ and Sofia Pedro¹, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Bristol-Myers Squibb, Hopewell, NJ
Background/Purpose: Comparative research has gained attention in the field of Rheumatology. Evaluations of baseline characteristics in patients receiving similar treatments are critical in the…
Abstract Number: 2517 • 2014 ACR/ARHP Annual Meeting
Long-Term Clinical, Structural, and Functional Consequences of Not Adopting Treatment in MTX Suboptimal Responders
Josef Smolen¹, Ronald F. van Vollenhoven², Stefan Florentinus³, Yijie Zhou⁴, Benoit Guerette⁴ and Arthur Kavanaugh⁵, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²The Karolinska Institute, Stockholm, Sweden, ³AbbVie, Rungis, France, ⁴AbbVie, Inc., North Chicago, IL, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Methotrexate (MTX) is used as first line therapy for treatment of rheumatoid arthritis (RA). Current recommendations state that therapy should be adjusted if patients…
Abstract Number: 2516 • 2014 ACR/ARHP Annual Meeting
Reasons and Risk Factor for Discontinuation of Biologic Agents in Rheumatoid Arthritis Patients
Kenya Terabe¹, Toshihisa Kojima¹, Nobunori Takahashi^1,2, Koji Funahashi³, Atsushi Kaneko⁴, Yuji Hirano⁵, Yasuhide Kanayama⁶, Yuichiro Yabe⁷ and Naoki Ishiguro¹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²65 Tsurumai-cho, Showa-ku, Nagoya University Graduate School of Medicine, Nagoya, Japan, ³Orthopedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya Medical Center, Nagoya, Japan, ⁵Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, ⁶Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, ⁷Rheumatology, JCHO Tokyo Shinjuku Medical Center, Tokyo, Japan
Background/Purpose Rheumatoid arthritis (RA) patients who failed a first biologic agent due to any reasons have the option of switching to a second one along…
Abstract Number: 2515 • 2014 ACR/ARHP Annual Meeting
Serum Survivin in Early Rheumatoid Arthritis
Adrian Levitsky¹, Malin Erlandsson², Maria Bokarewa² and Ronald F. van Vollenhoven³, ¹The Karolinska Institute,Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Stockholm, Sweden, ²Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ³Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden
Background/Purpose: The proto-oncogene survivin regulates cell division and inhibits apoptosis. Elevated levels may be found in patients with rheumatoid arthritis (RA) and their presence has…
Abstract Number: 2514 • 2014 ACR/ARHP Annual Meeting
Biological Treatment for Rheumatoid Arthritis (RA): A Fifteen Years Multicentric Overview
Vittorio Grosso¹, Roberto Gorla², Piercarlo Sarzi-Puttini³, Fabiola Atzeni⁴, Raffaele Pellerito⁵, Enrico Fusaro⁶, Giuseppe Paolazzi⁷, Pier Andrea Rocchetta⁸, Ennio Giulio Favalli⁹, Antonio Marchesoni¹⁰ and Roberto Caporali¹¹, ¹Division of Rheumatology,, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ²Reumatologia, Spedali Civili, Brescia, Italy, ³Rheumatology Unit, University Hospital L Sacco, Milano, Italy, ⁴Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ⁵Rheumatology, Ospedale Mauriziano, Turin, Italy, ⁶Department of Rheumatology, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Turin, Italy, ⁷Rheumatology, Santa Chiara Hospital, Trento, Italy, ⁸Struttura di Reumatologia A.S.O. «SS.Antonio e Biagio e C.Arrigo», Alessandria, Italy, ⁹Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, ¹⁰Department of Rheumatology, Gaetano Pini Institute, Milano, Italy, ¹¹Rheumatology, Division of Rheumatology, University of Pavia, IRCCS Policlinico San Matteo, Pavia, Italy
Background/Purpose During the last fifteen years, the role of biologics in the management of RA, the number of available biologics, and the recommendations of use,…
Abstract Number: 2533 • 2014 ACR/ARHP Annual Meeting
Utility of the American-European Consensus Group and American College of Rheumatology Classification Criteria for Sjögren’s Syndrome in Patients with Systemic Autoimmune Diseases in the Clinical Setting
Gabriela Hernandez-Molina¹, Carmen Ávila-Casado², Carlos Núñez-Álvarez³, Carlos Hernández-Hernández⁴, Maria Luisa Calderillo⁴, Martha Marroquín⁴, Claudia Recillas-Gispert⁵, Juanita Romero-Díaz³ and Jorge Sánchez-Guerrero⁶, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ²Pathology, University Health Network, Toronto Canada., Toronto, ON, Canada, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁴Dental Service, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁵Ophtalmology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁶Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: To evaluate the feasibility and performance of the AECG and ACR Classification Criteria for Sjögren’s syndrome (SS) in patients with systemic autoimmune diseases. Methods:…
Abstract Number: 2532 • 2014 ACR/ARHP Annual Meeting
Characteristics of Primary Sjögren Syndrome in the Black Population of Martinique
Katlyne Polomat¹, Serge Arfi², Lauren Brunier-Agot³, Véronique Dehlinger⁴, Michel DeBandt³, Georges Jean Baptiste⁵ and Christophe Deligny⁶, ¹Centre Hospitalier universitaire de Fort de France, Fort de France, Martinique, ²Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, ³Rheumatology, Centre Hospitalier universitaire de Fort de France, Fort de France, Martinique, ⁴Rheumatology, Centre Hospitalier universitaire de Fort de France, Fort De France - Martinique, Martinique, ⁵Rheumatology, Centre Hospitalier Universitaire de Fort de France, Fort de France, Guadeloupe, ⁶Internal Medicine, CHU Fort de France, Fort de France, France
Background/Purpose: There is very limited data on the clinical, biological characteristics and evolution of primary Sjögren syndrome (pSS) in black patients of African origin. And…
Abstract Number: 2531 • 2014 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Patients with Sjogren’s Syndrome: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Charat Thongprayoon², Karn Wijarnpreecha³, Wisit Cheungpasitporn², Praveen Ratanasrimetha⁴ and Promporn Suksaranjit⁵, ¹Department of Internal medicine, Bassett medical center, Cooperstown, NY, ²Department of Medicine, Mayo clinic, Rochester, MN, ³Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁴Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand, ⁵Department of Cardiology, University of Utah School of Medicine, Salt Lake City, UT
Risk of Venous Thromboembolism in Patients with Sjogren's Syndrome: A Systematic Review and Meta-analysisBackground/Purpose: Venous thromboembolism (VTE) is a common medical problem with a significant…
Abstract Number: 2530 • 2014 ACR/ARHP Annual Meeting
PRE.MARK-TNF Test Based on Iga-Specific Autoantigens Predicts Therapy Response in Rheumatoid Arthritis Patients Treated with TNFα Inhibitors
Karl Skriner¹, Jörg Hollidt², Gerd Burmester³ and Zoltan Konthur⁴, ¹Department of Rheumatology and Clinical Immunology, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Drug Response DX GmbH, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Drug Response DX GmbH, Hennigsdorf, Germany
Background/Purpose One third of rheumatoid arthritis patients treated with biologicals targeting TNFα are therapy non-responders. We have earlier investigated the difference in seroreactivity of patients…
Abstract Number: 2529 • 2014 ACR/ARHP Annual Meeting
Efficacy of Infliximab, Adalimumab, and Tocilizumab Can be Improved Under the Baseline ADAMTS5 Selection
Kensei Tsuzaka^1,2, Yoko Akiyama² and Masayoshi Nagata¹, ¹Division of Rheumatology, Iruma Heart Hospital, Iruma, Saitama, Japan, ²Kaytee Bio, Co&Ltd, Funabashi, Chiba, Japan
a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) mRNA level. In this study presented here, we investigated whether the efficacy of these biologics could…
Abstract Number: 2528 • 2014 ACR/ARHP Annual Meeting
Efficacy Meta-Analysis of Randomized Controlled Trials (RCTs) of Biologics in Methotrexate-Naive Patients with Early Rheumatoid Arthritis
Yusuf Yazici¹, Chunqiao Luo² and Christopher Swearingen³, ¹New York University Hospital for Joint Diseases, New York, NY, ²University of Arkansas, Biostatistics, Little Rock, AR, ³Pediatrics and Biostatistics, University of Arkansas, Little Rock, AR
Background/Purpose NNT analysis is a useful tool for putting RCT efficacy results into perspective in patient care. For clinical decision making, the NNT is a…
Abstract Number: 2527 • 2014 ACR/ARHP Annual Meeting
The Effect of Biological Agents on Work in Patients with Chronic Inflammatory Arthritides: A Meta-Analysis of Randomized Controlled Trials and Controlled Cohorts
Amandine Tubery¹, Cristel Castelli¹, Florence Erny¹, Françoise Barchechath-Flaisler¹, Sabrina Dadoun², Bruno Fautrel³ and Cecile Gaujoux Viala¹, ¹Nîmes University Hospital, Rheumatology Department, Nimes, France, ²Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d’Epidémiologie et de Santé Publique, paris, France, ³Rheumatology, UPMC Paris 06 University, GRC 08, Paris France and Pitié Salpétrière Hospital Paris France, Paris, France
Background/Purpose: The addition of biological agents in treatment strategies in chronic inflammatory arthritides have improved the possibility of controlling disease activity and slowing the progression…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].